Silicone adhesive multilayer foam dressings as adjuvant prophylactic therapy to prevent hospital-acquired pressure ulcers: a pragmatic noncommercial multicentre randomized open-label parallel-group medical device trial

被引:19
|
作者
Beeckman, D. [1 ,2 ,3 ]
Fourie, A. [1 ]
Raepsaet, C. [1 ]
Van Damme, N. [1 ]
Manderlier, B. [1 ]
De Meyer, D. [1 ]
Beele, H. [4 ]
Smet, S. [4 ]
Demarre, L. [5 ]
Vossaert, R. [5 ]
de Graaf, A. [6 ]
Verhaeghe, L. [7 ]
Vandergheynst, N. [7 ]
Hendrickx, B. [8 ]
Hanssens, V. [8 ]
Keymeulen, H. [9 ]
Vanderwee, K. [10 ]
Van De Woestijne, J. [11 ]
Verhaeghe, S. [1 ]
Van Hecke, A. [1 ]
Savoye, I. [12 ]
Harrison, J. [12 ]
Vrijens, F. [12 ]
Hulstaert, F. [12 ]
机构
[1] Univ Ghent, Dept Publ Hlth & Primary Care, Univ Ctr Nursing & Midwifery, Skin Integr Res Grp SKINT, Ghent, Belgium
[2] Royal Coll Surgeons Ireland, Sch Nursing & Midwifery, Dublin, Ireland
[3] Orebro Univ, Sch Hlth Sci, Orebro, Sweden
[4] Univ Ghent, Wound Care Ctr, Ghent, Belgium
[5] AZ St Elisabeth, Zottegem, Oost Vlaanderan, Belgium
[6] Univ Hosp Leuven, Nursing Ctr Excellence, Wound Care Support Team, Leuven, Belgium
[7] AZ Maria Middelares, Ghent, Belgium
[8] Univ Hosp Brussels UZB, Dept Plast Surg, Brussels, Belgium
[9] OLV Ziekenhuis Aalst, Aalst, Oost Vlaanderan, Belgium
[10] OLV van Lourdes Ziekenhuis Waregem, Waregem, West Vlaanderan, Belgium
[11] AZ Groeninge, Kortrijk, West Vlaanderan, Belgium
[12] Belgian Hlth Care Knowledge Ctr KCE, Brussels, Belgium
关键词
CLINICAL EFFECTIVENESS;
D O I
10.1111/bjd.19689
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background Silicone adhesive multilayer foam dressings are used as adjuvant therapy to prevent hospital-acquired pressure ulcers (PUs). Objectives To determine whether silicone foam dressings in addition to standard prevention reduce the incidence of PUs of category 2 or worse compared with standard prevention alone. Methods This was a multicentre, randomized controlled medical device trial conducted in eight Belgian hospitals. At-risk adult patients were centrally randomized (n = 1633) to study groups based on a 1 : 1 : 1 allocation: experimental groups 1 (n = 542) and 2 (n = 545) - pooled as the treatment group - and the control group (n = 546). The experimental groups received PU prevention according to hospital protocol, and a silicone foam dressing on the relevant body sites. The control group received standard of care. The primary endpoint was the incidence of a new PU of category 2 or worse at the studied body sites. Results In the intention-to-treat population (n = 1605), PUs of category 2 or worse occurred in 4 center dot 0% of patients in the treatment group and 6 center dot 3% in the control group [relative risk (RR) 0 center dot 64, 95% confidence interval (CI) 0 center dot 41-0 center dot 99, P = 0 center dot 04]. Sacral PUs were observed in 2 center dot 8% and 4 center dot 8% of the patients in the treatment group and the control group, respectively (RR 0 center dot 59, 95% CI 0 center dot 35-0 center dot 98, P = 0 center dot 04). Heel PUs occurred in 1 center dot 4% and 1 center dot 9% of patients in the treatment and control groups, respectively (RR 0 center dot 76, 95% CI 0 center dot 34-1 center dot 68, P = 0 center dot 49). Conclusions Silicone foam dressings reduce the incidence of PUs of category 2 or worse in hospitalized at-risk patients when used in addition to standard of care. The results show a decrease for the sacrum, but no statistical difference for the heel and trochanter areas.
引用
收藏
页码:52 / 61
页数:10
相关论文
共 5 条
  • [1] Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial
    Chen, Yu-Pei
    Liu, Xu
    Zhou, Qin
    Yang, Kun-Yu
    Jin, Feng
    Zhu, Xiao-Dong
    Shi, Mei
    Hu, Guo-Qing
    Hu, Wei-Han
    Sun, Yan
    Wu, Hong-Fen
    Wu, Hui
    Lin, Qin
    Wang, Hui
    Tian, Ye
    Zhang, Ning
    Wang, Xi-Cheng
    Shen, Liang-Fang
    Liu, Zheng-Zheng
    Huang, Jing
    Luo, Xiu-Ling
    Li, Ling
    Zang, Jian
    Mei, Qi
    Zheng, Bao-Min
    Yue, Dan
    Xu, Jing
    Wu, San-Gang
    Shi, Yan-Xia
    Mao, Yan-Ping
    Chen, Lei
    Li, Wen-Fei
    Zhou, Guan-Qun
    Sun, Rui
    Guo, Rui
    Zhang, Yuan
    Xu, Cheng
    Lv, Jia-Wei
    Guo, Ying
    Feng, Hui-Xia
    Tang, Ling-Long
    Xie, Fang-Yun
    Sun, Ying
    Ma, Jun
    [J]. LANCET, 2021, 398 (10297): : 303 - 313
  • [2] Effectiveness of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in weight management services (STRIVE study): a multicentre, open-label, parallel-group, randomized controlled trial
    Papamargaritis, Dimitris
    Al-Najim, Werd
    Lim, Jonathan Z. M.
    Crane, James
    Bodicoat, Danielle H.
    Barber, Shaun
    Lean, Michael
    McGowan, Barbara
    O'Shea, Donal
    Webb, David R.
    Wilding, John P. H.
    Roux, Carel W. le
    Davies, Melanie J.
    [J]. LANCET REGIONAL HEALTH-EUROPE, 2024, 39
  • [3] Tolerability and efficacy of vortioxetine versus SSRIs in elderly with major depression. Study protocol of the VESPA study: a pragmatic, multicentre, open-label, parallel-group, superiority, randomized trial
    Ostuzzi, Giovanni
    Gastaldon, Chiara
    Barbato, Angelo
    D'Avanzo, Barbara
    Tettamanti, Mauro
    Monti, Igor
    Aguglia, Andrea
    Aguglia, Eugenio
    Alessi, Maria Chiara
    Amore, Mario
    Bartoli, Francesco
    Biondi, Massimo
    Bortolaso, Paola
    Callegari, Camilla
    Carra, Giuseppe
    Caruso, Rosangela
    Cavallotti, Simone
    Crocamo, Cristina
    D'Agostino, Armando
    De Fazio, Pasquale
    Di Natale, Chiara
    Giusti, Laura
    Grassi, Luigi
    Martinotti, Giovanni
    Nose, Michela
    Papola, Davide
    Purgato, Marianna
    Rodolico, Alessandro
    Roncone, Rita
    Tarsitani, Lorenzo
    Turrini, Giulia
    Zanini, Elisa
    Amaddeo, Francesco
    Ruggeri, Mirella
    Barbui, Corrado
    [J]. TRIALS, 2020, 21 (01)
  • [4] Tolerability and efficacy of vortioxetine versus SSRIs in elderly with major depression. Study protocol of the VESPA study: a pragmatic, multicentre, open-label, parallel-group, superiority, randomized trial
    Giovanni Ostuzzi
    Chiara Gastaldon
    Angelo Barbato
    Barbara D’Avanzo
    Mauro Tettamanti
    Igor Monti
    Andrea Aguglia
    Eugenio Aguglia
    Maria Chiara Alessi
    Mario Amore
    Francesco Bartoli
    Massimo Biondi
    Paola Bortolaso
    Camilla Callegari
    Giuseppe Carrà
    Rosangela Caruso
    Simone Cavallotti
    Cristina Crocamo
    Armando D’Agostino
    Pasquale De Fazio
    Chiara Di Natale
    Laura Giusti
    Luigi Grassi
    Giovanni Martinotti
    Michela Nosé
    Davide Papola
    Marianna Purgato
    Alessandro Rodolico
    Rita Roncone
    Lorenzo Tarsitani
    Giulia Turrini
    Elisa Zanini
    Francesco Amaddeo
    Mirella Ruggeri
    Corrado Barbui
    [J]. Trials, 21
  • [5] Intensive compared with less intensive blood pressure control to prevent adverse cardiac remodelling in children with chronic kidney disease (HOT-KID): a parallel-group, open-label, multicentre, randomised, controlled trial
    Sinha, Manish D.
    Gu, Haotian
    Douiri, Abdel
    Cansick, Janette
    Finlay, Eric
    Gilbert, Rodney
    Kerecuk, Larissa
    Lunn, Andrew
    Maxwell, Heather
    Morgan, Henry
    Shenoy, Mohan
    Shroff, Rukshana
    Subramaniam, Pushpa
    Tizard, Jane
    Tse, Yincent
    Rezavi, Reza
    Simpson, John M.
    Chowienczyk, Phil J.
    [J]. LANCET CHILD & ADOLESCENT HEALTH, 2023, 7 (01): : 26 - 36